{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:34:25Z","timestamp":1791984865380,"version":"4.4.0"},"reference-count":45,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["grant #21 cm0106476"],"award-info":[{"award-number":["grant #21 cm0106476"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["JP17H06329"],"award-info":[{"award-number":["JP17H06329"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["20K09422"],"award-info":[{"award-number":["20K09422"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008886","name":"Princess Takamatsu Cancer Research Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008886","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,15]]},"abstract":"<jats:p>Cleavage of erythropoietin-producing hepatocellular ephrin receptor A2 (EphA2) triggers malignant progression and yields an N-terminal fragment (EphA2-NF) detectable in sera from patients with pancreatic ductal carcinoma. We established a quantitative automated chemiluminescence immunoassay for EphA2-NF and evaluated serum EphA2-NF levels as a biomarker to diagnose pancreatic ductal carcinoma in the test and validation cohorts. The EphA2-NF value was elevated (above the cutoff: mean \u00b1 SD) in more than half of the patients with stage I\/II pancreatic ductal carcinoma. Among patients receiving standard chemotherapy for pancreatic ductal carcinoma [gemcitabine plus nab-paclitaxel (GnP)], the median survival time of patients with elevated serum EphA2-NF was half that of patients with values below the cutoff. Patients with intraductal papillary mucinous neoplasm (IPMN), a precancerous pancreatic ductal carcinoma lesion, also show high serum EphA2 levels, which are associated with an increase in pancreatic duct size and the development of pancreatic ductal carcinoma in some cases. IHC showed loss of EphA2-NF staining in IPMN with pancreatic ductal carcinoma, but not in the normal epithelium or IPMN without pancreatic ductal carcinoma, regardless of the histologic grade. These results suggest that EphA2 cleavage is an essential event that occurs very early in pancreatic ductal carcinoma development, and that the consequent release of EphA2-NF can be detected in the serum. Thus, serum EphA2-NF could be a diagnostic biomarker for very early-stage pancreatic ductal carcinoma and pancreatic ductal carcinoma development from high-risk IPMN and as a prognostic biomarker after chemotherapy with GnP.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>EphA2 N-terminus deletion is involved in pancreatic ductal carcinoma development from high-risk IPMN and EphA2-NF produced by cleavage can be used as a serum biomarker to diagnose pancreatic ductal carcinoma and predict pancreatic ductal carcinoma development from high-risk IPMN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0087","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T09:37:56Z","timestamp":1692783476000},"page":"1862-1874","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2155-2379","authenticated-orcid":true,"given":"Shinya","family":"Sato","sequence":"first","affiliation":[{"name":"1Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan."},{"name":"2Department of Pathology, Kanagawa Cancer Center Hospital, Yokohama, Japan."},{"name":"3Morphological Analysis Laboratory, Kanagawa Cancer Center Research Institute, Yokohama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6276-1956","authenticated-orcid":true,"given":"Masatoshi","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"4Research and Development, Abbott Japan LLC, Chiba, Japan."},{"name":"5Department of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1052-0101","authenticated-orcid":true,"given":"Takeshi","family":"Terashima","sequence":"additional","affiliation":[{"name":"6Advanced Preventive Medical Sciences Research Center, Kanazawa University Hospital, Kanazawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1551-1837","authenticated-orcid":true,"given":"Soichiro","family":"Morinaga","sequence":"additional","affiliation":[{"name":"7Department of Gastroenterological Surgery, Kanagawa Cancer Center Hospital, Yokohama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0056-7010","authenticated-orcid":true,"given":"Yohei","family":"Miyagi","sequence":"additional","affiliation":[{"name":"1Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan."},{"name":"2Department of Pathology, Kanagawa Cancer Center Hospital, Yokohama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3655-6339","authenticated-orcid":true,"given":"Eisaku","family":"Yoshida","sequence":"additional","affiliation":[{"name":"3Morphological Analysis Laboratory, Kanagawa Cancer Center Research Institute, Yokohama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9178-9777","authenticated-orcid":true,"given":"Toru","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"3Morphological Analysis Laboratory, Kanagawa Cancer Center Research Institute, Yokohama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3909-0782","authenticated-orcid":true,"given":"Motoharu","family":"Seiki","sequence":"additional","affiliation":[{"name":"8Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7113-3319","authenticated-orcid":true,"given":"Shuichi","family":"Kaneko","sequence":"additional","affiliation":[{"name":"8Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4480-0029","authenticated-orcid":true,"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[{"name":"9Department of Gastroenterology, Kanagawa Cancer Center Hospital, Yokohama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3383-9131","authenticated-orcid":true,"given":"Taro","family":"Yamashita","sequence":"additional","affiliation":[{"name":"8Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4539-888X","authenticated-orcid":true,"given":"Naohiko","family":"Koshikawa","sequence":"additional","affiliation":[{"name":"5Department of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Japan."},{"name":"10Clinical Cancer Proteomics Laboratory, Kanagawa Cancer Center Research Institute, Yokohama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"2023091514053844700_bib1","doi-asserted-by":"crossref","first-page":"14637","DOI":"10.1074\/jbc.M807598200","article-title":"Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis","volume":"284","author":"Irie","year":"2009","journal-title":"J Biol Chem"},{"key":"2023091514053844700_bib2","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1083\/jcb.200304018","article-title":"EphA kinase activation regulates HGF-induced epithelial branching morphogenesis","volume":"162","author":"Miao","year":"2003","journal-title":"J Cell Biol"},{"key":"2023091514053844700_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/14728222.2011.538682","article-title":"Emerging strategies for EphA2 receptor targeting for cancer therapeutics","volume":"15","author":"Tandon","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"2023091514053844700_bib4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/35000008","article-title":"Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation","volume":"2","author":"Miao","year":"2000","journal-title":"Nat Cell Biol"},{"key":"2023091514053844700_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2009.04.009","article-title":"EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt","volume":"16","author":"Miao","year":"2009","journal-title":"Cancer Cell"},{"key":"2023091514053844700_bib6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.fob.2013.01.002","article-title":"Ephexin4-mediated promotion of cell migration and anoikis resistance is regulated by serine 897 phosphorylation of EphA2","volume":"3","author":"Kawai","year":"2013","journal-title":"FEBS Open Bio"},{"key":"2023091514053844700_bib7","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1038\/s41388-021-01714-8","article-title":"Oncogenic functions and therapeutic targeting of EphA2 in cancer","volume":"40","author":"Wilson","year":"2021","journal-title":"Oncogene"},{"key":"2023091514053844700_bib8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1158\/0008-5472.CAN-09-1845","article-title":"Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy","volume":"70","author":"Zhuang","year":"2010","journal-title":"Cancer Res"},{"key":"2023091514053844700_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jgg.2021.02.011","article-title":"EphA2: a promising therapeutic target in breast cancer","volume":"48","author":"Zhao","year":"2021","journal-title":"J Genet Genomics"},{"key":"2023091514053844700_bib10","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.2353\/ajpath.2009.080473","article-title":"Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis","volume":"174","author":"Taddei","year":"2009","journal-title":"Am J Pathol"},{"key":"2023091514053844700_bib11","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/cncr.10749","article-title":"Human osteosarcoma expresses specific ephrin profiles: implications for tumorigenicity and prognosis","volume":"95","author":"Varelias","year":"2002","journal-title":"Cancer"},{"key":"2023091514053844700_bib12","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.1038\/onc.2008.328","article-title":"Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor","volume":"27","author":"Wykosky","year":"2008","journal-title":"Oncogene"},{"key":"2023091514053844700_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1475-2867-10-41","article-title":"Soluble ephrin a1 is necessary for the growth of HeLa and SK-BR3 cells","volume":"10","author":"Alford","year":"2010","journal-title":"Cancer Cell Int"},{"key":"2023091514053844700_bib14","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1158\/0008-5472.CAN-14-2798","article-title":"Proteolysis of EphA2 converts it from a tumor suppressor to an oncoprotein","volume":"75","author":"Koshikawa","year":"2015","journal-title":"Cancer Res"},{"key":"2023091514053844700_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00428-016-1934-9","article-title":"Immunohistochemical demonstration of EphA2 processing by MT1-MMP in invasive cutaneous squamous cell carcinoma","volume":"469","author":"Tatsukawa","year":"2016","journal-title":"Virchows Arch"},{"key":"2023091514053844700_bib16","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.21873\/anticanres.12722","article-title":"Activated EphA2 processing by MT1-MMP is involved in malignant transformation of ovarian tumours in vivo","volume":"38","author":"Takahashi","year":"2018","journal-title":"Anticancer Res"},{"key":"2023091514053844700_bib17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1083\/jcb.201205176","article-title":"EphA2 cleavage by MT1-MMP triggers single cancer cell invasion via homotypic cell repulsion","volume":"201","author":"Sugiyama","year":"2013","journal-title":"J Cell Biol"},{"key":"2023091514053844700_bib18","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/cas.15638","article-title":"Proteolytic cleavage of membrane proteins by membrane type-1 MMP regulates cancer malignant progression","volume":"114","author":"Ikeda","year":"2023","journal-title":"Cancer Sci"},{"key":"2023091514053844700_bib19","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/ijms23010146","article-title":"Matrix metalloproteinases shape the tumor microenvironment in cancer progression","volume":"23","author":"Niland","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2023091514053844700_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1023\/A:1023087113214","article-title":"Role of pericellular proteolysis by membrane-type 1 matrix metalloproteinase in cancer invasion and angiogenesis","volume":"22","author":"Seiki","year":"2003","journal-title":"Cancer Metastasis Rev"},{"key":"2023091514053844700_bib21","doi-asserted-by":"crossref","first-page":"e3134","DOI":"10.1038\/cddis.2017.545","article-title":"Specific detection of soluble EphA2 fragments in blood as a new biomarker for pancreatic cancer","volume":"8","author":"Koshikawa","year":"2017","journal-title":"Cell Death Dis"},{"key":"2023091514053844700_bib22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.seminoncol.2021.02.003","article-title":"KRAS mutation in pancreatic cancer","volume":"48","author":"Luo","year":"2021","journal-title":"Semin Oncol"},{"key":"2023091514053844700_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2023091514053844700_bib24","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/MPA.0000000000000368","article-title":"Early detection of sporadic pancreatic cancer: summative review","volume":"44","author":"Chari","year":"2015","journal-title":"Pancreas"},{"key":"2023091514053844700_bib25","doi-asserted-by":"crossref","first-page":"e476","DOI":"10.1016\/S1470-2045(13)70172-4","article-title":"Improvement of surgical results for pancreatic cancer","volume":"14","author":"Hartwig","year":"2013","journal-title":"Lancet Oncol"},{"key":"2023091514053844700_bib26","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.cgh.2021.10.008","article-title":"Serum carboxypeptidase activity and genotype-stratified CA19\u20139 to detect early-stage pancreatic cancer","volume":"20","author":"Tanaka","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023091514053844700_bib27","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/MOG.0000000000000770","article-title":"Early detection of pancreatic cancer: current state and future opportunities","volume":"37","author":"Trikudanathan","year":"2021","journal-title":"Curr Opin Gastroenterol"},{"key":"2023091514053844700_bib28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12893-022-01667-z","article-title":"Comparison of CEA and CA19\u20139 as a predictive factor for recurrence after curative gastrectomy in gastric cancer","volume":"22","author":"Shibata","year":"2022","journal-title":"BMC Surg"},{"key":"2023091514053844700_bib29","first-page":"900","article-title":"Lewis antigennegative pancreatic cancer: an aggressive subgroup","volume":"56","author":"Liu","year":"2020","journal-title":"Int J Oncol"},{"key":"2023091514053844700_bib30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s10038-020-00826-5","article-title":"Aberrant expression of a novel circular RNA in pancreatic cancer","volume":"66","author":"Seimiya","year":"2021","journal-title":"J Hum Genet"},{"key":"2023091514053844700_bib31","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/ijc.31900","article-title":"CA19\u20139 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation","volume":"144","author":"Honda","year":"2019","journal-title":"Int J Cancer"},{"key":"2023091514053844700_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40364-017-0109-4","article-title":"Development of a fully automated chemiluminescence immunoassay for urine monomeric laminin-gamma2 as a promising diagnostic tool of non-muscle invasive bladder cancer","volume":"5","author":"Nakagawa","year":"2017","journal-title":"Biomark Res"},{"key":"2023091514053844700_bib33","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"key":"2023091514053844700_bib34","first-page":"155","article-title":"Prognostic and predictive factors in breast cancer by immunohistochemical analysis","volume":"11","author":"Allred","year":"1998","journal-title":"Mod Pathol"},{"key":"2023091514053844700_bib35","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.suc.2015.05.010","article-title":"Screening for pancreatic cancer","volume":"95","author":"Wada","year":"2015","journal-title":"Surg Clin North Am"},{"key":"2023091514053844700_bib36","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.7150\/thno.26650","article-title":"Chemoresistance transmission via exosome-mediated EphA2 transfer in pancreatic cancer","volume":"8","author":"Fan","year":"2018","journal-title":"Theranostics"},{"key":"2023091514053844700_bib37","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1248\/bpb.b17-00446","article-title":"Emerging and diverse functions of the EphA2 noncanonical pathway in cancer progression","volume":"40","author":"Zhou","year":"2017","journal-title":"Biol Pharm Bull"},{"key":"2023091514053844700_bib38","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/jjco\/hyf093","article-title":"Main pancreatic duct dilatation: a sign of high risk for pancreatic cancer","volume":"32","author":"Tanaka","year":"2002","journal-title":"Jpn J Clin Oncol"},{"key":"2023091514053844700_bib39","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00006676-199303000-00004","article-title":"Serum levels of CA 19\u20139 and CA 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease","volume":"8","author":"von Rosen","year":"1993","journal-title":"Pancreas"},{"key":"2023091514053844700_bib40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pan.2016.10.004","article-title":"Comparison of the prognostic impact of pre- and post-operative CA19\u20139, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma","volume":"17","author":"Kondo","year":"2017","journal-title":"Pancreatology"},{"key":"2023091514053844700_bib41","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5114\/ceji.2016.65139","article-title":"Diagnostic value of selected markers and apoptotic pathways for pancreatic cancer","volume":"41","author":"Slotwinski","year":"2016","journal-title":"Cent Eur J Immunol"},{"key":"2023091514053844700_bib42","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.2147\/CMAR.S304719","article-title":"Serum exosomal EphA2 is a prognostic biomarker in patients with pancreatic cancer","volume":"13","author":"Wei","year":"2021","journal-title":"Cancer Manag Res"},{"key":"2023091514053844700_bib43","doi-asserted-by":"crossref","first-page":"eaaz2878","DOI":"10.1126\/scitranslmed.aaz2878","article-title":"Molecular and functional extracellular vesicle analysis using nanopatterned microchips monitors tumor progression and metastasis","volume":"12","author":"Zhang","year":"2020","journal-title":"Sci Transl Med"},{"key":"2023091514053844700_bib44","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.3390\/cancers12092625","article-title":"Prospective study using plasma apolipoprotein A2-isoforms to screen for high-risk status of pancreatic cancer","volume":"12","author":"Sato","year":"2020","journal-title":"Cancers"},{"key":"2023091514053844700_bib45","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.bbrc.2018.02.170","article-title":"Serum apolipoprotein A2 isoforms in autoimmune pancreatitis","volume":"497","author":"Kobayashi","year":"2018","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0087\/3359590\/crc-23-0087.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/9\/1862\/3364510\/crc-23-0087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/9\/1862\/3364510\/crc-23-0087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T10:07:01Z","timestamp":1694772421000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/9\/1862\/729065\/EphA2-Proteolytic-Fragment-as-a-Sensitive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,15]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0087","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.24147619","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147607","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147619.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147631","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147598","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147613.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147616.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147661.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147610.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147655","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147643","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147655.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147652.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147643.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147646.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147649.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147595","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147640","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147652","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147640.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147604","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147628","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147616","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147634.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147631.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147637.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147598.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147628.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147595.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147622.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147625.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147661","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147658.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147592","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147607.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147604.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147637","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147625","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147649","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147613","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147601","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147601.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147592.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147658","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147622","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147610","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147646","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24147634","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6837526.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6837526","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]}}}